Structure and Functional Binding Epitope of V-domain Ig Suppressor of T-cell Activation (VISTA)
N. Mehta, S. Maddineni, I. I. Mathews, A. P. Sperberg, P.-S. Huang, J. R. Cochran
Abstract
V-domain Ig Suppressor of T cell Activation (VISTA) is an immune checkpoint protein that inhibits the T - cell response against cancer. Similar to PD-1 and CTLA-4, antibodies that block VISTA signaling can release the brakes of the immune system and promote tumor clearance. VISTA has an Ig-like fold, but little is known about its structure and mechanism of action. Here, we report a 1.85 [A] crystal structure of the human VISTA extracellular domain and highlight structural features that make VISTA unique among B7 family members. Through fine-epitope mapping, we also identify solvent-exposed residues that underlie binding to a clinically relevant anti-VISTA antibody. This antibody-binding region is also shown to interact with V-set and Ig domain-containing 3 (VSIG3), the recently proposed functional binding partner of VISTA. The structure and functional epitope determined here will help guide future drug development efforts against this important checkpoint target.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Membrane-coupled conformational switching of VISTA regulates immune checkpoint signaling via CC' loop accessibility
Aravindhan Ganesan, Varun Reddy, Norman Ly·bioRxiv·Feb 10, 2026
- On the same side: The immune regulatory protein Vista and its ligands interact in cis
Karina Smorodinsky-Atias, Gil Wiseglass, … Rotem Rubinstein·Protein SciencePeer-reviewed·Dec 22, 2025
- Expression of immune checkpoint VISTA represents a differentiated state of cancer cells and plays a role in regulating actin cytoskeleton
- VISTA-induced tumor suppression by a four amino acid intracellular motif
Yan Zhao, Tina Andoh, … Joshua James Gruber·bioRxiv·Jan 5, 2025
- Dual Targeting for Enhanced Tumor Immunity: Conditionally Active CD28xVISTA Bispecific Antibodies Promote Myeloid-Driven T-Cell Activation
Thomas Thisted, F. Donelson Smith, … Edward Htun van der Horst·bioRxiv·Apr 7, 2025
- Soluble CTLA-4 raises the threshold for T-cell activation and modulates anti-tumour immunity
P. T. Kennedy, E. L. Saulters, … L. N. Dahal·bioRxiv·Jun 5, 2023